Cellebrite DI (NASDAQ:CLBT) CFO Sells $683,602.92 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CFO David Barter sold 41,734 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the sale, the chief financial officer owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT traded down $0.38 during mid-day trading on Thursday, reaching $16.13. 1,121,366 shares of the company’s stock were exchanged, compared to its average volume of 1,995,589. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of 57.61, a PEG ratio of 2.05 and a beta of 1.17. The business’s fifty day moving average price is $13.64 and its 200-day moving average price is $14.55. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds have recently bought and sold shares of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC increased its holdings in Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after buying an additional 43,898 shares during the last quarter. Invesco Ltd. lifted its position in Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares in the last quarter. First Trust Advisors LP purchased a new position in shares of Cellebrite DI during the 2nd quarter valued at about $341,000. Finally, Marshall Wace LLP bought a new position in shares of Cellebrite DI in the second quarter worth approximately $4,472,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CLBT shares. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC dropped their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, DA Davidson initiated coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.